Investment Thesis
Phio Pharmaceuticals exhibits exceptional balance sheet strength with $17M cash, zero debt, and pristine liquidity supporting a dramatic revenue surge (+2987.5% YoY), yet the company remains deeply unprofitable with $4.0M operating losses and negative cash flow. Improving profitability metrics (net income loss -21.7%, EPS +80.6% YoY) suggest successful early commercialization, but unclear path to profitability and ongoing cash burn present material fundamental risks.
Strengths
- Exceptional balance sheet: $17M cash, zero long-term debt, 14.43x current ratio provides 4+ years cash runway at current burn rate
- Dramatic revenue acceleration at +2987.5% YoY from early-stage commercialization phase
- Improving profitability trajectory: net income losses shrinking 21.7% YoY, diluted EPS improving 80.6% YoY
Risks
- Massive operating cash burn of $4M offsetting revenue growth; company not yet self-funding operations
- Extreme negative margins (-1803.9% operating, -1732.9% net) indicate fundamental unprofitability at current scale
- Pharmaceutical commercialization highly binary; minimal revenue base ($231K) creates significant execution risk for achieving scale
- Operating cash burn duration unclear; despite strong cash position, sustained losses without revenue acceleration threaten viability
Key Metrics to Watch
- Quarterly revenue growth rate and gross margins as products scale
- Operating cash burn trajectory and path to break-even operations
- Cash runway duration at current burn rate vs. revenue growth acceleration needed
Financial Metrics
Revenue
231.0K
Net Income
-4.0M
EPS (Diluted)
$-0.86
Free Cash Flow
-4.0M
Total Assets
17.4M
Cash
17.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,803.9%
Net Margin
-1,732.9%
ROE
-24.3%
ROA
-23.0%
FCF Margin
-1,732.9%
Balance Sheet & Liquidity
Current Ratio
14.43x
Quick Ratio
14.43x
Debt/Equity
0.00x
Debt/Assets
5.5%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:02:50.724317 |
Data as of: 2026-03-31 |
Powered by Claude AI